Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.36 |
| ▸ | NPY4R | P50391 | 4/20 | 0.36 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23789219 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21477710 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21897649 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL19046493 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18937600 | 1.00 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20889012 | 0.99 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18911084 | 0.96 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23353475 | 0.94 | FAP (0.43) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22643670 | 0.93 | FAP (0.45) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL21861811 | 0.93 | FAP (0.45) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | FAP 3796/4885NPY5R 1908/4885NPY4R 2031/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885NPY5R 1593/4885NPY4R 2363/4885 |
| US-10239862-B2 | Benzazepine compounds, conjugates, and uses thereof | TLR8, TLR3, TLR5 | FAP 3807/4885NPY5R 2567/4885NPY4R 3054/4885 |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885NPY5R 1593/4885NPY4R 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.